China, India At Core Of GSK Plan To Double Emerging-Markets Earnings
This article was originally published in PharmAsia News
Executive Summary
China and India and the drug prices it charges in the two countries are central to U.K.-based GlaxoSmithKline's plan to compete with three other multinational drug makers in emerging markets